Skip to content

Close the Gap in Dementia Detection and Care

Fast, scientifically validated cognitive screening and assessment for earlier, more accurate dementia detection and care planning in primary care.

Book a Demo  

Trusted by Leading Organizations Across the Country

 

Primary Care’s Dementia Dilemma

  • Uncertainty delays diagnosis, care planning, and proper risk adjustment, which limits effectiveness of clinicians.

  • Specialists are overwhelmed—referrals don’t happen fast enough and there can be a wait time of 3-6 months.

  • Traditional tools like the MMSE are limited and lack sensitivity for accurate, early screening.

Frame 21
See How Creyos Compares to Other Pen and Paper Solutions
Creyos
Traditional Tools
Ease of Administration

Fast and efficient—can be completed remotely without physician oversight

Inefficient and difficult to administer—require physician oversight

Focus Area

Designed for early detection of subtle changes in cognitive function

Designed specifically for individuals with potentially significant cognitive issues

Brain Region Alignment

Associated with distinct brain regions and functions, as validated by fMRI

No alignment to brain regions or specific cognitive domains

Sensitivity

Sensitive to factors that can impact brain health, such as: lifestyle, mental health concerns, neurological conditions, etc.

Minimal utility for the general population with limited sensitivity to certain conditions and disorders (e.g., ADHD, depression, anxiety, etc.)

Clinical Insights

Utilizes 85,000+ participant normative databases to classify patients as below average, average or above average relative to their demographic group

Returns a single, non-specific number that provides little context or insight regarding areas of deficit

Longitudinal Monitoring

Excellent test-retest reliability—designed for longitudinal monitoring

Not well suited to longitudinal monitoring

Please note: The Creyos dementia protocol is not a standalone diagnostic tool. As with other Creyos Health assessments, any conclusions drawn from the Creyos dementia protocol should be paired with clinical interviews and observations, other mental health examinations or assessments administered, and other evaluations of the patient and/or the patient's family history

Room for Improvement in Today’s Approach

The MoCA

Specificity concern: Studies have reported low specificity, increasing the risk of false positives. In one review, specificity was as low as 35% depending on the context, which may reduce diagnostic accuracy in certain patient populations.¹

The MMSE

Limited Sensitivity and Ceiling effects: May miss early decline—one study found a 34% false negative rate using a cutoff of 24.² Its ceiling effect also makes it harder to distinguish normal aging from mild cognitive impairment (MCI).³

The Mini-Cog

Variable Sensitivity and Specificity: Performance varies by setting. Though sensitive to dementia, one study showed only 54% specificity, potentially limiting its reliability as a standalone screening tool for conditions like dementia.⁴

References

1. Kansagara, D., & Freeman, M. (2010). A Systematic Evidence Review of the Signs and Symptoms of Dementia and Brief Cognitive Tests Available in VA. Department of Veterans Affairs (US). https://www.ncbi.nlm.nih.gov/books/NBK49027
2. O’Bryant, S.E., Humphreys, J.D., Smith, G.E., Ivnik, R. J., Graff-Radford, N. R., Petersen, R. C., & Lucas, J. A. (2008). Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals. Arch Neurol, 65 (7), 963–967. https://doi.org/10.1001/archneur.65.7.963 
3. Trzepacz, P. T., Hochstetler, H., Wang, S., Walker, B., & Saykin, A. J. (2015). Relationship between the Montreal Cognitive Assessment and Mini-Mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatrics, 15 (107). https://doi.org/10.1186/s12877-015-0103-3
4. Kaufer, D. I., Williams, C. S., Braaten, A. J., Gill, K., Zimmerman, S., & Sloane, P. D. (2008). Cognitive Screening for Dementia and Mild Cognitive Impairment in Assisted Living: Comparison of 3 Tests. Journal of the American Medical Directors Association, 9(8), 586–593. https://doi.org/10.1016/j.jamda.2008.05.006

A Better Way to Detect, Diagnose, and Plan

Fast, Digital Cognitive Testing

Online screener, assessment, and questionnaires—clinically validated, age-normed and aligned to DSM-5 diagnostic criteria.
Digital Cognitive Testing-1

Clear Clinical Reports

Instant reports with actionable insights to support diagnosis and drive care pathways and coordinated interventions.
Reports-2

Designed for Primary Care Workflows

Works across team-based care models with EHR interoperability, no special training required, and remote testing ability.
Workflow-3

Backed by Decades of Scientific Research

Built on rigorous science—30 years of research, an 85,000 participant normative database, and validation in over 400 peer-reviewed studies.
Science-3
Digital Cognitive Testing-1 Digital Cognitive Testing-1 Reports-2 Workflow-3 Science-3

A Better Way to Detect, Assess, and Plan

Fast, Digital Cognitive Testing

Clear Clinical Reports

Designed for Primary Care Workflows

Backed by Decades of Scientific Research

Digital Cognitive Testing-1

Online screener, assessment, and questionnaires—clinically validated, age-normed, and aligned to DSM-5 diagnostic criteria.

From Detection to Care Planning, All Within Primary Care

Step 1: Streamlined Cognitive Testing

Patients complete a quick, task-based assessment on a tablet—no paperwork or specialist referrals needed.
Streamline Testing

Step 2: Assessments Aligned With the DSM-5 Built in

Administer the IADL, IQCODE, and mental health questionnaires directly in Creyos to measure activities of daily living, subjective decline, and neuropsychiatric symptoms, with results automatically added to the patient record.
Criteria-2

Step 3: Instant, Actionable Results

Providers receive real-time results with built-in clinical guidance to support interpretation and next steps.
Result

Step 4: Personalized Care Planning

Create tailored care plans within Creyos to support follow-up, documentation, and improved outcomes.
Care planning-3
Streamline Testing-1 Streamline Testing Criteria-2 Result Care planning-3

More Confident Assessment. Smarter Clinical Decisions. Better Performance.

Clinical Outcomes

Value Based Care Impact

Clinical Outcomes
  • Identify signs earlier—track cognitive decline over time.
  • Improve patient and family confidence in the diagnosis.
  • Tailor care plans before patients reach a crisis point.

Bring Early Dementia Detection Into Everyday Practice

Get a Demo  

Questions About Creyos? We Have Answers

How accurate is the Creyos dementia assessment compared to traditional neuropsychological testing?

Creyos has been validated as a more scalable and efficient alternative to neuropsychological testing, providing detailed insights into specific cognitive domains in a fraction of the time required for a full neuropsychological battery. Its tasks have demonstrated strong correlations with gold-standard neuropsychological tests, offering high convergent validity and supporting its use as an informative follow-up to initial screening.

Is Creyos sensitive enough to detect early signs of cognitive decline, including MCI?

Yes—Creyos is specifically designed to detect subtle cognitive changes often missed by screening tools like the MoCA or MMSE. It measures multiple domains, including memory and executive function, to help identify early decline, even if it has not yet affected everyday tasks or responses to simple screeners. A series of recent studies provide compelling support for integrating Creyos assessments into routine cognitive evaluations and leveraging it as an alternative to the MoCA or MMSE.

How does Creyos distinguish between cognitive issues due to dementia vs. depression or anxiety?

Creyos includes validated behavioral health assessments—the PHQ-9 for depression, GAD-7 for anxiety, and others—enabling providers to better differentiate between true cognitive decline and symptoms that may be caused or masked by mood disorders, substance abuse, or other factors.

How long does the dementia screener and assessment take, and who on the care team can administer it?

The dementia screener and assessment on the Creyos platform takes just 5 to 8 minutes to complete, depending on how much data needs to be collected. It’s fully digital and anyone on the care team can initiate the assessment, including medical assistants, nurses, or care coordinators, with results available immediately to support clinical decision making.

Can it be integrated into existing workflows like the Medicare Annual Wellness Visit or chronic care management?

Yes. The Creyos dementia assessment can be seamlessly integrated into existing workflows such as the Medicare Annual Wellness Visit (AWV), chronic care management (CCM), or routine primary care visits. It’s quick to administer, generates automated results, and requires no specialized training—making it easy to incorporate into standard care processes without adding burden to your team. Many providers use Creyos to meet cognitive assessment requirements under the AWV while also identifying early signs of impairment to support more proactive and personalized care.

Do results flow into an EHR, and can they be shared with the broader care team?

Yes! Creyos integrates with hundreds of EHRs. We offer flexible integration options—whether through direct API access or secure file transfer—to ensure that data is easily accessible alongside other clinical information. This supports more coordinated care, streamlined workflows, and better informed decision making across your team.

How does using Creyos support Medicare requirements for cognitive assessment and dementia care?

Creyos supports Medicare requirements by streamlining both cognitive assessment and care planning in a single platform. It enables fast, standardized cognitive testing as part of the Annual Wellness Visit (AWV), helping providers efficiently meet documentation requirements while identifying early signs of impairment. This is especially important under CMS-HCC V28, where a timely and accurate dementia diagnosis contributes to appropriate risk adjustment and care management.


Beyond assessment, Creyos offers built-in care plan creation to guide next steps for both the provider and patient. Clinicians use the results from the Creyos dementia assessment to document personalized care plans, including recommendations for follow-up testing, behavioral health support, medication management, caregiver guidance, and lifestyle modifications—ensuring compliance with Medicare expectations, while supporting better outcomes across the care continuum.

Can it help increase RAF scores under CMS-HCC V28 by supporting more accurate dementia coding?

Yes. Creyos helps providers identify signs of dementia that traditional screening tools often miss and supports the diagnostic specificity required under CMS-HCC V28.


Using a sensitive, scientifically validated digital screener and assessment, Creyos detects cognitive impairment across a full range of severity—from mild to moderate to severe. This enables earlier identification and more accurate differentiation of dementia stages, which is essential for compliant and specific coding under V28.

What’s the ROI—how does this tool contribute to quality measures, risk adjustment, or total cost of care?

Creyos helps health systems detect dementia earlier and more often—typically increasing detection rates from the typical 4-6% to 8-12% of their 65+ patient population. That translates to significantly more patients receiving timely diagnoses and care, and a meaningful financial impact: each additional diagnosis can add roughly $2,400 per member in RAF-adjusted reimbursement annually.


Early detection also leads to better care planning and fewer high cost events. Studies show that people with undiagnosed dementia are up to two times more likely to be hospitalized, and account for up to 40% higher healthcare costs. With Creyos, providers can intervene earlier—reducing preventable hospitalizations and ER visits, all of which lower total cost of care and support quality metrics around screening, care coordination, and chronic condition management.

Is the assessment appropriate and accessible for older adults across different languages, cultures, and education levels?

Absolutely. Creyos has been thoughtfully designed with accessibility at its core to ensure it works well for older adults across diverse languages, cultures, and education levels. The platform follows WCAG accessibility standards, including high contrast visuals, large and legible fonts, and intuitive layouts that are easy to navigate—even for those with limited digital experience. Creyos is also available in multiple languages, with audio instructions and simple, clear guidance to support individuals with lower literacy levels. This ensures a comfortable and inclusive experience for a wide range of patients, regardless of background.

Can it be self-administered or done remotely for patients who can’t come into the clinic?

While many health systems prefer to have assessments completed in-clinic, Creyos can be both self-administered and completed remotely. Patients can access Creyos from the comfort of their own home using a secure online link that can be sent via email—no special equipment or in-person visit required. This makes it especially convenient for those who have mobility challenges, live in remote areas, or simply prefer virtual care.

Is the platform HIPAA compliant and secure, and how is patient data managed?

Yes, the platform is fully HIPAA compliant and built with security at its core. All patient data is encrypted both in transit and at rest, and strict access controls are in place to ensure only authorized users can view sensitive information. We adhere to best practices in data protection and regularly audit our systems to maintain compliance and safeguard privacy. Data is stored in secure environments, and we provide clear protocols for managing, accessing, and, when necessary, deleting information in accordance with regulatory requirements.